Advertisement

Topics

J&J arthritis drug sirukumab raises safety concerns: FDA staff

04:40 EDT 31 Jul 2017 | Reuters

(Reuters) - Staff reviewers for the U.S. Food and Drug Administration noted on Monday that there was a trend of increased death with Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab compared with placebo.

Original Article: J&J arthritis drug sirukumab raises safety concerns: FDA staff

NEXT ARTICLE

More From BioPortfolio on "J&J arthritis drug sirukumab raises safety concerns: FDA staff"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...